Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer

Mark D. Pegram, MD
Published Online: Friday, Jul 14, 2017



Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Based on level 1 evidence, there is good data to support the use of pertuzumab (Perjeta) plus trastuzumab (Herceptin) with chemotherapy in the first line setting. This is then followed by T-DM1 in the second line, states Pegram.

This has set the standard of care for the HER2-postive metastatic breast cancer patient population, explains Pegram.
 


Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Based on level 1 evidence, there is good data to support the use of pertuzumab (Perjeta) plus trastuzumab (Herceptin) with chemotherapy in the first line setting. This is then followed by T-DM1 in the second line, states Pegram.

This has set the standard of care for the HER2-postive metastatic breast cancer patient population, explains Pegram.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
Publication Bottom Border
Border Publication